PRODUCTION ASSISTANCE FOR CELLULAR THERAPIES (PACT)- CELL PROCESSING FACILITIES CELL-TASK AREA 2, PCT0050-01: HESC-DERIVED CARDIOMYOCYTE PROGENITOR CE

细胞疗法生产协助 (PACT) - 细胞处理设施细胞任务区域 2，PCT0050-01：HESC 衍生的心肌细胞祖细胞 CE

• 批准号: 10470435
• 负责人: JOSEPH GOLD
• 金额: $ 25.17万
• 依托单位: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-10-20 至 2021-07-20
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10470435
• 关键词: Area; Cardiac Myocytes; Cell Therapy; Cells; Cities; Cyclic GMP; Doctor of Philosophy; Genetic; Laboratories; Procedures; Process; Production; Research; Research Personnel; Running; Study models; Suspension Culture; Technology; Translating; Translational Research; base; flasks; gene therapy; human embryonic stem cell; manufacturing facility; manufacturing process; medical schools; novel; porcine model; pre-clinical; progenitor

The Center for Biomedicine and Genetics (CBG) at City of Hope (COH) is a cGMP manufacturing facility dedicated to providing COH researchers and their collaborators support in all aspects of translational research, including expertise in translating laboratory-based procedures for novel and emerging cell and gene therapy technologies to pilot-scale pre-clinical cGLP processes and fully cGMP=compliant manufacturing processes. IN this proposal, they propose to supply human embryonic stem cell (hESC)-derived cardiomayocytes (CM) to PACT investigator, Joseph Wu, MD, PhD (Stanford School of Medicine), in support of his IND-enabling research for his submitted IND.

希望之城 (COH) 的生物医学和遗传学中心 (CBG) 是一家 cGMP 制造设施，致力于为 COH 研究人员及其合作者提供转化研究各个方面的支持，包括将基于实验室的程序转化为新型和新兴细胞的专业知识和基因治疗技术，以试点临床前 cGLP 流程和完全符合 cGMP 的制造流程。在这项提案中，他们提议向 PACT 研究者 Joseph Wu 医学博士（斯坦福大学医学院）提供人类胚胎干细胞 (hESC) 衍生的心肌细胞 (CM)，以支持他提交的 IND 的 IND 启用研究。